OSU pathology home page

Sanjay Mishra

Research Assistant Professor

Portrait of Sanjay Mishra

Phone:

614-404-4284

E-mail:

Email Dr. Mishra

Mailing Address:

840H Biomedical
Research Tower

460 W 12th Ave.

Columbus, OH 43210

Biosketch

Our lab focuses on understanding the role of microRNAs (miRNAs) and inflammatory molecules like S100A7 and PLCG2 in breast and lung cancer pathogenesis. My doctoral research identified novel circulating miRNA biomarkers for breast cancer detection and revealed miR-34a's regulatory role in triple-negative breast cancer (TNBC). Our team has uncovered key signaling molecules regulated by miRNAs that drive TNBC development and progression, with our findings published in high-impact journals such as Cancer Letters, Journal of Proteomics, and PROTEOMICS-Clinical Applications.

We also investigate the role of the pro-inflammatory molecule S100A7 in breast cancer progression and metastasis. Our studies have shown that S100A7 is highly expressed in TNBC and promotes cancer growth by modulating inflammatory and metastatic pathways. Using a novel inducible bi-transgenic mouse model, we demonstrated that S100A7 interacts with the RAGE and enhances cPLA2-mediated downstream signaling, thereby driving breast tumor growth and metastasis, particularly in TNBC.

In collaboration with Prof. Ramesh Ganju's and Kristin Stanford’s labs at Ohio State University Medical Wexner Center, we are also exploring the novel role of S100A7 in the tumor microenvironment (TME) and its links to obesity and racial disparities in TNBC. Our research shows that S100A7 is elevated in African American TNBC patients and promotes cancer growth and metastasis. We have developed a transgenic floxed mouse model and S100A7 neutralizing antibody to study S100A7's impact on the obese TME and cancer stem cell activity, highlighting its role in linking obesity to aggressive metastatic cancer.

Our lab also mentors graduate students and collaborates on projects investigating miRNA and protein signatures in lung cancer. Currently, we are examining the tumor-suppressive roles of miR-1 and PLCG2 inhibitors in multidrug-resistant lung cancer, aiming to develop novel therapeutic strategies for managing metastatic lung cancer.

Our research is published in esteemed journals such as the Journal of Experimental and Clinical Cancer Research, Cancer Research, Cell Death and Disease, British Journal of Dermatology, and Molecular Oncology. As part of the Pelotonia-funded research at OSU, I have engaged in professional development activities and collaborations with leading cancer biologists. My goal is to leverage my expertise in cancer biology to advance drug discovery and therapeutics, ultimately improving outcomes for patients with metastatic breast and lung cancers.

Grants

Phospholipase C gamma 2 (PLCG2): A promising therapeutic target against Metastatic Small Cell Lung Cancer (PI; DoD; 06/01/2024-05/31/2025).

Monocarboxylate transporter 1 as a novel therapeutic target against small cell lung cancer. (Co-I; DoD; 09/01/2023-08/31/2024)

Unravel the novel role of S100A7 and its functional partners in Metastatic Triple Negative Breast Cancer racial disparity. (Co-I; R01 NCI; 07/01/2024 - 06/30/2029)

Academic and Medical Appointments

2024-Present Research Assistant Professor, Department of Pathology, The Ohio State University, Columbus, OH

2022-2024 Research Scientist, Department of Pathology, The Ohio State University, Columbus, OH

2019-2022 Postdoctoral Fellow, Department of Pathology, The Ohio State University, Columbus, OH

2017-2019 Pelotonia Postdoctoral Fellow in Comprehensive Cancer Center, The Ohio State University, Columbus, OH

2016-2017 Postdoctoral Fellow, Department of Pathology, The Ohio State University, Columbus, OH

2012-2016 Senior Research Fellow, AcSIR, Council of Scientific and Industrial Research, New Delhi India

2010-2012 Junior Research Fellow, AcSIR, Council of Scientific and Industrial Research, New Delhi India

Education and Training

2016 Ph.D., AcSIR, Council of Scientific and Industrial Research, New Delhi India

2009 M.Sc. (Zoology Cytogenetics specialization), University of Calcutta, West Bengal, India

2007 B.Sc. (Zoology Hons), University of Calcutta, West Bengal, India

Selected Publications

Search in PubMed

  • Ahirwar DK, Peng B, Charan M, Misri S, Mishra S, Kaul K, Sassi S, Gadepalli VS, Siddiqui J, Miles WO, Ganju RK. Slit2/Robo1 signaling inhibits small-cell lung cancer by targeting β-catenin signaling in tumor cells and macrophages. Mol Oncol. 2023 May;17(5):839-856. doi: 10.1002/1878-0261.13289. Epub 2023 Jan 10. PubMed PMID: 35838343; PubMed Central PMCID: PMC10158774.
  • Wilkie T, Verma AK, Zhao H, Charan M, Ahirwar DK, Kant S, Pancholi V, Mishra S, Ganju RK. Lipopolysaccharide from the commensal microbiota of the breast enhances cancer growth: role of S100A7 and TLR4. Mol Oncol. 2022 Apr;16(7):1508-1522. doi: 10.1002/1878-0261.12975. Epub 2021 Nov 16. PubMed PMID: 33969603; PubMed Central PMCID: PMC8978520.
  • Misri S, Kaul K, Mishra S, Charan M, Verma AK, Barr MP, Ahirwar DK, Ganju RK. Cannabidiol Inhibits Tumorigenesis in Cisplatin-Resistant Non-Small Cell Lung Cancer via TRPV2. Cancers (Basel). 2022 Feb 24;14(5). doi: 10.3390/cancers14051181. PubMed PMID: 35267489; PubMed Central PMCID: PMC8909073.
  • Mishra S, Charan M, Shukla RK, Agarwal P, Misri S, Verma AK, Ahirwar DK, Siddiqui J, Kaul K, Sahu N, Vyas K, Garg AA, Khan A, Miles WO, Song JW, Bhutani N, Ganju RK. cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment. J Exp Clin Cancer Res. 2022 Feb 8;41(1):54. doi: 10.1186/s13046-021-02221-0. PubMed PMID: 35135586; PubMed Central PMCID: PMC8822829.
  • Kaul K, Benej M, Mishra S, Ahirwar DK, Yadav M, Stanford KI, Jacob NK, Denko NC, Ganju RK. Slit2-Mediated Metabolic Reprogramming in Bone Marrow-Derived Macrophages Enhances Antitumor Immunity. Front Immunol. 2021;12:753477. doi: 10.3389/fimmu.2021.753477. eCollection 2021. PubMed PMID: 34777365; PubMed Central PMCID: PMC8581492.
  • Ahirwar DK, Charan M, Mishra S, Verma AK, Shilo K, Ramaswamy B, Ganju RK. Slit2 Inhibits Breast Cancer Metastasis by Activating M1-Like Phagocytic and Antifibrotic Macrophages. Cancer Res. 2021 Oct 15;81(20):5255-5267. doi: 10.1158/0008-5472.CAN-20-3909. Epub 2021 Aug 16. PubMed PMID: 34400395; PubMed Central PMCID: PMC8631742.
  • Mishra S, Charan M, Verma AK, Ramaswamy B, Ahirwar DK, Ganju RK. Racially Disparate Expression of mTOR/ERK-1/2 Allied Proteins in Cancer. Front Cell Dev Biol. 2021;9:601929. doi: 10.3389/fcell.2021.601929. eCollection 2021. Review. PubMed PMID: 33996789; PubMed Central PMCID: PMC8120233.
  • Charan M, Das S, Mishra S, Chatterjee N, Varikuti S, Kaul K, Misri S, Ahirwar DK, Satoskar AR, Ganju RK. Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer. Cell Death Dis. 2020 Sep 17;11(9):774. doi: 10.1038/s41419-020-02992-y. PubMed PMID: 32943608; PubMed Central PMCID: PMC7498597.
  • Charan M, Verma AK, Hussain S, Misri S, Mishra S, Majumder S, Ramaswamy B, Ahirwar D, Ganju RK. Molecular and Cellular Factors Associated with Racial Disparity in Breast Cancer. Int J Mol Sci. 2020 Aug 18;21(16). doi: 10.3390/ijms21165936. Review. PubMed PMID: 32824813; PubMed Central PMCID: PMC7460595.
  • Garg AA, Jones TH, Moss SM, Mishra S, Kaul K, Ahirwar DK, Ferree J, Kumar P, Subramaniam D, Ganju RK, Subramaniam VV, Song JW. Electromagnetic fields alter the motility of metastatic breast cancer cells. Commun Biol. 2019;2:303. doi: 10.1038/s42003-019-0550-z. eCollection 2019. PubMed PMID: 31428691; PubMed Central PMCID: PMC6687738.
  • Brodsky SV, Ganju R, Mishra S, Ivanov I, Fadda P, Wang H, Barth RF. Genomic Analysis of an Obesity Paradox: A Microarray Study of the Aortas of Morbidly Obese Decedents With Mild and Severe Atherosclerosis. Crit Pathw Cardiol. 2019 Mar;18(1):57-60. doi: 10.1097/HPC.0000000000000169. PubMed PMID: 30747767; PubMed Central PMCID: PMC6375103.
  • Das S, Kaul K, Mishra S, Charan M, Ganju RK. Cannabinoid Signaling in Cancer. Adv Exp Med Biol. 2019;1162:51-61. doi: 10.1007/978-3-030-21737-2_4. Review. PubMed PMID: 31332734.
  • Rai G, Suman S, Mishra S, Shukla Y. Evaluation of growth inhibitory response of Resveratrol and Salinomycin combinations against triple negative breast cancer cells. Biomed Pharmacother. 2017 May;89:1142-1151. doi: 10.1016/j.biopha.2017.02.110. Epub 2017 Mar 12. PubMed PMID: 28298074.
  • Suman S, Mishra S, Shukla Y. Toxicoproteomics in human health and disease: an update. Expert Rev Proteomics. 2016 Dec;13(12):1073-1089. doi: 10.1080/14789450.2016.1252676. Epub 2016 Nov 11. Review. PubMed PMID: 27813434.
  • Mishra S, Ahirwar DK, Ganju RK. Psoriasin (S100A7): a novel mediator of angiogenesis. Br J Dermatol. 2016 Dec;175(6):1141-1142. doi: 10.1111/bjd.15141. PubMed PMID: 27996128.
  • Suman S, Basak T, Gupta P, Mishra S, Kumar V, Sengupta S, Shukla Y. Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer. J Proteomics. 2016 Oct 4;148:183-93. doi: 10.1016/j.jprot.2016.07.033. Epub 2016 Aug 3. PubMed PMID: 27498393.
  • Srivastava AK, Mishra S, Ali W, Shukla Y. Protective effects of lupeol against mancozeb-induced genotoxicity in cultured human lymphocytes. Phytomedicine. 2016 Jun 15;23(7):714-24. doi: 10.1016/j.phymed.2016.03.010. Epub 2016 Apr 11. PubMed PMID: 27235710.